Evaluation of QTc liability for PF-05251749 in the presence of potential circadian rhythm modification.
PF-05251749 is a dual inhibitor of casein kinase 1/, key regulators of circadian rhythm. Due to its mechanism of action, PF-05251749 may also change the QTc circadian rhythm, which may confound detection of drug-induced QT prolongation. In this analysis, a nonlinear mixed-effect model including a multi-oscillator function was developed in addition to fitting the pre-specified linear mixed-effect concentration-QTc model, to identify QTc liability of PF-05251749 in the presence of potential circadian rhythm change. The modeling results suggested lack of clinically meaningful QTc prolongation (upper bound of 90% confidence interval for ∆∆QTc < 10ms) and that the drug-induced QTc circadian rhythm change was not present. However, simulation results indicated that inference of drug-induced QTc prolongation could be misleading if drug effect on QTc circadian rhythm is not properly addressed. The modeling and simulation results suggest that pre-specification of the concentration-QTc model should be reconsidered for drugs with circadian rhythm modulation potential.